Ishani Barai, Rashmi G. Mathew, Sobha Sivaprasad, Christin Henein
{"title":"信息图：玻璃体内阿弗利百普治疗和延长方案在渗出性年龄相关性黄斑变性中的疗效和安全性：ALTAIR研究","authors":"Ishani Barai, Rashmi G. Mathew, Sobha Sivaprasad, Christin Henein","doi":"10.1038/s41433-024-03336-2","DOIUrl":null,"url":null,"abstract":"<p>Reference to original article:</p><p>Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173-1187.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":"14 1","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study\",\"authors\":\"Ishani Barai, Rashmi G. Mathew, Sobha Sivaprasad, Christin Henein\",\"doi\":\"10.1038/s41433-024-03336-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Reference to original article:</p><p>Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173-1187.</p>\",\"PeriodicalId\":12125,\"journal\":{\"name\":\"Eye\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41433-024-03336-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03336-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
原文参考：Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators.玻璃体内阿弗利百普治疗和延长方案对渗出性年龄相关性黄斑变性的疗效和安全性：ALTAIR：一项随机对照试验的 52 周和 96 周结果。Adv Ther.2020年3月；37（3）：1173-1187。
Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study
Reference to original article:
Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173-1187.
期刊介绍：
Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists.
Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
